TY - JOUR T1 - Prediction of abnormal left ventricular geometry in patients without cardiovascular disease through machine learning: An ECG-based approach JF - medRxiv DO - 10.1101/2020.11.10.20228981 SP - 2020.11.10.20228981 AU - Eleni Angelaki AU - Maria E. Marketou AU - Georgios D. Barmparis AU - Alexandros Patrianakos AU - Panos E. Vardas AU - Fragiskos Parthenakis AU - Giorgos P. Tsironis Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/11/13/2020.11.10.20228981.1.abstract N2 - Cardiac remodeling is recognized as an important aspect of cardiovascular disease (CVD) progression. Machine learning (ML) techniques were applied on basic clinical parameters and electrocardiographic features for detecting abnormal left ventricular geometry (LVG), even before the onset of left ventricular hypertrophy (LVH), in a population without established CVD. After careful screening, we enrolled 528 subjects with and without essential hypertension, but no other indications of CVD. All patients underwent a full echocardiographic evaluation and were classified into 3 groups; normal geometry (NG), concentric remodeling without LVH (CR), and LVH. Abnormal LVG was identified as increased relative wall thickness (RWT) and/or left ventricular mass index (LVMi). We trained nonlinear predictive ML models, to classify subjects with abnormal LVG and calculated SHAP values to perform feature importance and interaction analysis. Hypertension, age, body mass index over the Sokolow-Lyon voltage, QRS-T angle, and QTc duration were some of the most important features. Our model was able to distinguish NG from all others (CR+LVH), with accuracy 86%, specificity 75%, sensitivity 95%, and area under the receiver operating curve (AUC/ROC) 0.89. We also trained our model to classify NG and CR (NG+CR) against those with established LVH, with accuracy 89%, specificity 97%, sensitivity 50%, and AUC/ROC 0.85. Our ML algorithm effectively detects abnormal LVG even at early stages. Innovative solutions are needed to improve risk stratification of patients without established CVD, especially in primary care settings, and ML may enable this direction.Competing Interest StatementProfessor Vardas has to report personal fees from MENARINI INTERNATIONAL, DEAN MEDICUS, SERVIER, EUROPEAN SOCIETY OF CARDIOLOGY, HYGEIA HOSPITALS GROUPS LTD, BAEYR. The other authors have nothing to declare.Funding StatementThis work was partial supported by the Institute of Theoretical and Computational Physics of the University of Crete.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was carried out in accordance with the Declaration of Helsinki, the protocol was approved by the Hospital Ethics Committee and the Research Ethics Committe of the University of Crete. (Ν.4521/2018) All patients gave written informed consent to their participation in the study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data underlying this article cannot be shared publicly due to the privacy of individuals that participated in the study. The data will be shared on reasonable request to the corresponding author. ER -